Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Astellas Pharma Inc. Stories

2014-04-16 12:31:30

NORTHBROOK, Ill., April 16, 2014 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that it has reached an agreement with the U.S. Department of Justice to resolve civil claims regarding the marketing of MYCAMINE(®) (micafungin sodium) for injection. Under the agreement, Astellas will pay $7.3 million to the settling parties. The Department of Justice had investigated Astellas for alleged off-label...

2014-04-15 08:31:27

NEW YORK, April 15, 2014 /PRNewswire-USNewswire/ -- The National Kidney Foundation (NKF) announced today, during National Donate Life Month, that Astellas Pharma US, Inc. was named the first-ever National Presenting Sponsor for the Kidney Walk. Through this partnership, Astellas will support more than 85 Kidney Walk events being held in major cities across the country. "Our partnership with NKF exemplifies what Astellas and these walks are all about - enabling patients to be their own...

2014-04-03 08:28:53

TOKYO and SAN FRANCISCO, April 3, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI(®) (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet...

2014-03-24 16:24:53

TOKYO, March 24, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) today announced that Astellas has obtained marketing approval of their oral androgen receptor signaling inhibitor, XTANDI(®) capsules 40mg (development code: MDV3100; generic name: enzalutamide) for the treatment of patients with castration-resistant prostate cancer in Japan. Astellas filed the application for approval in Japan in May 2013. XTANDI is a once-daily, oral androgen receptor signaling inhibitor that acts on...

2014-03-19 00:22:17

TOKYO, March 19, 2014 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Company, Limited ("Daiichi Sankyo," President and CEO: Joji Nakayama) today announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds. The collaboration enables each party to promote innovative new medicine research and development. This is the first time that a compound library...

2014-03-06 23:30:58

Deeper engagement with Association of Strategic Alliance Professionals reflects pharmaceutical leader’s focus on elevating the practice of alliance management within healthcare industry. Canton, Mass. (PRWEB) March 06, 2014 The Association of Strategic Alliance Professionals (ASAP), the world’s leading professional association dedicated to the practice of alliance management, today announced that leading pharmaceutical company Astellas Pharma Inc. has upgraded to Global Member....

2014-02-28 08:24:51

TOKYO, Feb. 28, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo:4503, "Astellas") announced today that the company has amended the License, Co-Development and Co-Promotion Agreement on isavuconazole under co-development with Basilea Pharmaceutica Ltd. ("Basilea"). Based on this amendment, the territories subject to the License Agreement have been changed to reflect that Astellas will be responsible for all regulatory filings and will exclusively commercialize and assume full...

2014-02-27 08:29:07

-- If isavuconazole is approved for invasive mucormycosis, QIDP status provides a five-year extension of market exclusivity -- NORTHBROOK, Ill., Feb. 27, 2014 /PRNewswire/ -- Astellas Pharma Global Development, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive mucormycosis (also known as...

2014-01-22 12:23:39

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Pharmerging Markets 2012-2016TechNavio's analysts forecast the Pharmerging market to grow at a CAGR of 12.44 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in healthcare spending. The Pharmerging market has also been witnessing an increase in partnerships among vendors. However, the price pressure could pose a challenge to the...

2014-01-06 04:21:45

In-license Vaccine Technology for Respiratory Syncytial Virus (RSV) from Mymetics TOKYO, ROCKVILLE, Md. and EPALINGES, Switzerland, Jan. 6, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases. The partnership was established to support Astellas' goal of building a global vaccine franchise and launched...